Understanding S1P Receptor Modulator Therapy for Ulcerative Colitis
Written by: CDHF
Updated: September 16th, 2024
Inflammatory Bowel Disease is a challenging and often debilitating condition that affects approximately 322,600 people in Canada. Ulcerative colitis (UC) and Crohn’s disease are forms of inflammatory bowel disease (IBD), that is characterized by chronic inflammation of the gastrointestinal tract. Specifically, UC affects the colon and rectum, leading to symptoms such as abdominal pain, diarrhea, and rectal bleeding. Managing UC is crucial because uncontrolled inflammation can lead to severe complications, including increased risk of colon cancer, significant weight loss, and reduced quality of life. Part of managing UC is taking medications, which are essential as they help control inflammation, reduce symptoms, and maintain remission. At CDHF, we are dedicated to helping those with UC by providing information on the latest treatments. One promising development is S1P receptor modulator therapy (oral capsules). Let’s explore what this therapy is, how it works, and its potential benefits for those with UC.
What Are S1P Receptor Modulators?
In UC, the immune system becomes inappropriately activated in the colon, leading to inflammation that causes the symptoms of UC. This inflammation requires white blood cells to be able to travel from lymph nodes around the bowel into the bowel itself. The lymph nodes serve as a “hotel” where white blood cells stay until they are needed to cause inflammation. One of the signals that tells white blood cells to leave the bowel and enter the bowel to cause inflammation is a molecule called S1P (sphingosine-1-phosphate). Think of S1P as the ringing of fire alarm that tells white blood cells to its time to leave the lymph node and come to the colon.
S1P receptor modulators are a type of medication designed to help manage autoimmune and inflammatory diseases, including ulcerative colitis. These drugs target specific receptors called sphingosine-1-phosphate (S1P) receptors found on the surface of various cells, including those in the immune system. By influencing these receptors, S1P modulators can help regulate immune responses and reduce inflammation.
How Do They Work?
S1P receptor modulators, which include Etrasimod (Velsipity™) and Ozanimod (Zeposia®) are chemicals which block the ability of white blood cells to respond to the S1P signal (in other words, it makes more of them sleep through the alarm). As a result, fewer of the White blood cells leave the lymph node and travel to the colon, reducing the severity of inflammation, and allowing your colon to heal and your symptoms to improve.
The way S1P receptor modulators work can be broken down into a few key steps:
- Targeting S1P Receptors: These medications attach to S1P receptors on immune cells. Think of these receptors as tiny locks, and the medication as the key that fits into them.
- Sequestering Immune Cells: Once the medication binds to the S1P1 receptors on lymphocytes (a type of white blood cell), it causes these cells to be held in the lymph nodes. This prevents them from moving to the gut, where they would normally contribute to inflammation.
- Reducing Inflammation: By keeping these immune cells away from the gut, S1P modulators reduce the inflammation and immune response that causes the symptoms of ulcerative colitis. This helps in controlling the disease and providing relief from the symptoms.
- Promoting Healing: Additionally, these medications help the lining of the colon heal by reducing ongoing inflammation, which is crucial for long-term disease management.
Why Are They Important for Ulcerative Colitis?
S1P receptor modulators can be prescribed for individuals with moderate to severely active ulcerative colitis who have not responded adequately to conventional therapy, have lost response to previous treatments, or cannot tolerate biologic therapies. S1P receptor modulators offer a new oral treatment option that can be easier to take and manage compared to injectable medications.
Benefits
- Symptom Relief: By reducing the number of immune cells that reach the gut, these drugs help to alleviate the painful and uncomfortable symptoms of UC.
- Maintaining Remission: These medications are not just for treating flare-ups; they also help maintain remission, which means keeping the disease under control over the long term.
- Mucosal Healing: Research has shown that S1P receptor modulators can help the lining of the colon heal, which is a vital part of achieving long-term relief from UC.
If you or a loved one is living with ulcerative colitis, we encourage you to talk to your healthcare provider about whether S1P receptor modulator therapy might be a suitable option. Together, we can work towards a future where everyone with UC can enjoy a healthier, more comfortable life.
